https://orcid.org/0000-0003-0723-6094
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Objective
Social cognitive deficits are prevalent after traumatic brain injury (TBI). Despite this, few remediation studies exist. This study aimed to demonstrate ‘proof of concept’ for a novel group treatment that comprehensively targeted the core processes of social cognition.
Design
Pre-post case study with two participants, “Greg” and “Aaron”, living with severe TBI, with three assessment time points.
Method
Participants were screened at baseline to confirm social cognitive deficits: Greg exhibited difficulties with emotion perception and detecting hints; Aaron with detecting sarcasm and hints. Both reported everyday social problems. Participants then completed the 14-week group treatment program (SIFT IT). Feasibility and outcome measures were repeated post-group and at three-month follow-up.
Results
The study procedure was implemented with 100% assessment and 89% SIFT IT session attendance, albeit with a lack of proxy-report measures. Both participants described procedures as acceptable, although suggested more group participants could be beneficial. They both demonstrated reliable improvements (RCI > 1.96) on relevant social cognitive measures. Qualitative feedback corroborated findings: Greg reported generalization of therapeutic gains, Aaron reported increased self-awareness but nominal generalization.
Conclusion
Feasibility and limited efficacy outcomes established ‘proof of concept’ of SIFT IT. Findings will inform the study protocol for a larger randomized-controlled trial.
Acknowledgement
This research was supported by an Australian Government Research Training Program (RTP) Scholarship and a Centre for Research Excellence (CRE) in Brain Recovery Seed Grant.
Declaration of interest
The Awareness of Social Inference Test-Short (TASIT-S) is sold commercially by the Australasian Society for the Study of Brain Impairment (ASSBI), for which one co-author (SM) receives royalties. Otherwise, there are no conflicts of interest in the research reported in this article.